Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tennessee Gets Pseudoephedrine Pharmacy Sale, CHPA Education Program

This article was originally published in The Tan Sheet

Executive Summary

Tennessee is the sixth state to enact a law restricting pseudoephedrine products to pharmacy sale

You may also be interested in...



Anti-meth campaign

CHPA is joining Partnership for a Drug-Free America and Missouri, Arizona chapters of the American Academy of Pediatrics in an effort to reduce number of teens abusing methamphetamine. Two-year 1educational campaign will focus on St. Louis, Phoenix metro areas and will involve PSAs, print ads and brochures. PDFA estimates costs of the ads and PR messages will range from $8 mil. to $10 mil., mostly donated pro bono. One PSA will feature actor/musician Henry Rollins exploding the engine of a car to demonstrate meth's effects on the heart, while another will show a guided tour of a filthy meth lab. The pseudoephedrine in OTC cough/cold remedies can be illegally converted into meth...

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098073

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel